Aligos Therapeutics

#DidYouKnow that only 27% of people with chronic HBV are diagnosed according to the @WHO? The @CDCgov recommends that every adult get screened for hepatitis B at least once – have you been screened? #HepTestingDay Learn more: hhs.gov/hepatitis/awar…

Our team is on the ground for the 33rd European Congress on Obesity! We presented preclinical data showing that combination of our THR-β Agonist with an incretin receptor agonist leads to synergistic weight loss in DIO mice. #ECO2026

The 2026 #EASL Congress is coming up on May 27-30 in Barcelona! Our team will present 10 posters at the conference with updates on our programs for chronic HBV, MASH/obesity, and more. Read the press release: investor.aligos.com/news-releases/…

Today we reported recent business progress and financial results for Q1 2026. Read the press release: investor.aligos.com/news-releases/…

May is #HepatitisAwarenessMonth – and we will be sharing chronic HBV insights, stories, and resources all month long. In the video, see some of the key symptoms and complications that can result from chronic #HBV infection over time. Learn more: aligos.com/patients/chron…

That’s a wrap on the International Conference on Antiviral Research (ICAR)! Shoutout to Aligos team members David McGowan and Jordi Verheyen for presenting posters at this important event, put on by the International Society for Antiviral Research. #ICAR2026

#CompanyNews – Stay tuned for our Q1 earnings report on May 7, 2026. Learn more here: investor.aligos.com/news-releases/…

Our team recently attended the @AACR Annual Meeting in San Diego! Thanks to Tongfei Wu and Heleen Roose for sharing preclinical data on our oral PD-L1 small molecule inhibitors, ALG-093940 and ALG-094295 in a poster presentation. #AACR26

Last week, we announced several major milestones for our chronic Hepatitis B virus (#HBV) program, demonstrating the continued progress with CAM-E and its potential to be a best/first-in-class treatment for chronic HBV infection. Learn more: investor.aligos.com/news-and-media…

#DidYouKnow that many #liver diseases can be prevented or managed early? The @CDCgov recommends all adults are screened for hepatitis B – where chronic infection can lead to liver disease and liver cancer – at least once in their life. Have you been screened? #WorldLiverDay

#InTheNews – Check out this @FierceBiotech article by @JamesPharma on our recent deal w/ Amoytop to develop & commercialize our capsid assembly modulator in Greater China for chronic #HBV infection: fiercebiotech.com/biotech/aligos…

#CompanyNews – Today, we announced an exclusive license deal with Amoytop Biotech to develop and commercialize our capsid assembly modulator for chronic hepatitis B virus (#HBV) infection in greater China. To learn more, read the press release: investor.aligos.com/news-releases/…

#CompanyNews – Today, we announced interim analysis results from the Phase 2 B-SUPREME Study and that the @US_FDA granted Fast Track Designation for our CAM-E for the treatment of chronic hepatitis B virus infection. Read the press release: investor.aligos.com/news-releases/…

We're looking forward to attending the World Hepatitis Summit by @Hep_Alliance next month. The event brings together policymakers, patients, medical professionals, and industry members with the shared goal to address the challenges of viral #hepatitis.

#DidYouKnow that over 254M people are living with chronic Hepatitis B infection? Learn more from the @WHO here: who.int/news-room/fact…

What are the #pharma trends to watch in 2026? In a recent @PharmaOnline article, our CEO, Lawrence Blatt lays out 9 trends to track, including dealmaking and out-licensing to regulatory changes and the challenges and innovations shaping drug development: pharmaceuticalonline.com/doc/pharma-tre…

Today we recognize the incredible people who power our work here at Aligos. Thank you to all of our employees for your commitment to patients, to advancing science, and to supporting each other every step of the way. #EmployeeAppreciationDay

Today we reported recent business progress and financial results for Q4 and full year 2025. Learn more here: investor.aligos.com/news-releases/…

Scenes from the Conference on Retroviruses and Opportunistic Infections (CROI)! Thanks to Stanley Wang, MD, for presenting our Ph1 study results for our #HBV program, & to Megan Fitzgerald, PhD, for sharing updates on our pan-coronavirus program.

#CompanyNews – Stay tuned for our Q4 and full year 2025 earnings report on March 5, 2026. Learn more here: investor.aligos.com/news-releases/…